WO2007123722A3 - Methods for prediction and prognosis of cancer, and monitoring cancer therapy - Google Patents

Methods for prediction and prognosis of cancer, and monitoring cancer therapy Download PDF

Info

Publication number
WO2007123722A3
WO2007123722A3 PCT/US2007/007965 US2007007965W WO2007123722A3 WO 2007123722 A3 WO2007123722 A3 WO 2007123722A3 US 2007007965 W US2007007965 W US 2007007965W WO 2007123722 A3 WO2007123722 A3 WO 2007123722A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
prognosis
prediction
methods
monitoring
Prior art date
Application number
PCT/US2007/007965
Other languages
French (fr)
Other versions
WO2007123722A2 (en
Inventor
Scott Wilhelm
Original Assignee
Bayer Pharmaceuticals Corp
Scott Wilhelm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp, Scott Wilhelm filed Critical Bayer Pharmaceuticals Corp
Priority to JP2009503038A priority Critical patent/JP2009532029A/en
Priority to CA002648106A priority patent/CA2648106A1/en
Priority to EP07754481A priority patent/EP2002264A2/en
Publication of WO2007123722A2 publication Critical patent/WO2007123722A2/en
Publication of WO2007123722A3 publication Critical patent/WO2007123722A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Abstract

The present invention also relates to biomarkers and the use of biomarkers for the prediction and prognosis of cancer as well as the use of biomarkers to monitor the efficacy of cancer treatment.
PCT/US2007/007965 2006-03-31 2007-03-30 Methods for prediction and prognosis of cancer, and monitoring cancer therapy WO2007123722A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2009503038A JP2009532029A (en) 2006-03-31 2007-03-30 Cancer prediction and prognostic methods and cancer treatment monitoring
CA002648106A CA2648106A1 (en) 2006-03-31 2007-03-30 Methods for prediction and prognosis of cancer, and monitoring cancer therapy
EP07754481A EP2002264A2 (en) 2006-03-31 2007-03-30 Methods for prediction and prognosis of cancer, and monitoring cancer therapy

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US78769306P 2006-03-31 2006-03-31
US60/787,693 2006-03-31
US90168207P 2007-02-16 2007-02-16
US60/901,682 2007-02-16

Publications (2)

Publication Number Publication Date
WO2007123722A2 WO2007123722A2 (en) 2007-11-01
WO2007123722A3 true WO2007123722A3 (en) 2008-05-08

Family

ID=38430446

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/007965 WO2007123722A2 (en) 2006-03-31 2007-03-30 Methods for prediction and prognosis of cancer, and monitoring cancer therapy

Country Status (4)

Country Link
EP (1) EP2002264A2 (en)
JP (1) JP2009532029A (en)
CA (1) CA2648106A1 (en)
WO (1) WO2007123722A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
JP2002534468A (en) 1999-01-13 2002-10-15 バイエル コーポレイション ω-Carboxyaryl-substituted diphenylureas as p38 kinase inhibitors
EP2324825A1 (en) 2002-02-11 2011-05-25 Bayer Healthcare LLC Aryl ureas with angiogenesis inhibiting activity
ATE366108T1 (en) 2003-05-20 2007-07-15 Bayer Pharmaceuticals Corp DIARYL UREAS FOR PDGFR-MEDIATED DISEASES
NZ580384A (en) 2003-07-23 2011-03-31 Bayer Pharmaceuticals Corp 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions
RU2010123381A (en) * 2007-11-09 2011-12-20 Дженентек, Инк. (Us) METHOD AND COMPOSITIONS FOR DIAGNOSTIC USE IN CANCER PATIENTS
GB0814722D0 (en) * 2008-08-12 2008-09-17 Ge Healthcare Ltd Treatment monitoring
WO2010022227A1 (en) * 2008-08-20 2010-02-25 Schering Corporation Methods for monitoring il-10 therapy
EP2350663A2 (en) * 2008-10-21 2011-08-03 Bayer HealthCare LLC Identification of signature genes associated with hepatocellular carcinoma
CN105074467B (en) * 2013-04-25 2018-06-15 株式会社Cbs生物科学 Improve the analysis method of the sensibility of molecular targeted therapy hepatocellular carcinoma
US20190207946A1 (en) * 2016-12-20 2019-07-04 Google Inc. Conditional provision of access by interactive assistant modules
EP3682345B1 (en) 2018-08-07 2021-11-24 Google LLC Assembling and evaluating automated assistant responses for privacy concerns

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007015947A2 (en) * 2005-07-29 2007-02-08 Bayer Healthcare Llc Methods and kits for the prediction of therapeutic success, recurrence free and overall survival in cancer therapies

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007015947A2 (en) * 2005-07-29 2007-02-08 Bayer Healthcare Llc Methods and kits for the prediction of therapeutic success, recurrence free and overall survival in cancer therapies

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
CANCER RESEARCH 1 OCT 2004, vol. 64, no. 19, 1 October 2004 (2004-10-01), pages 7099 - 7109, ISSN: 0008-5472 *
CARLOMAGNO FRANCESCA ET AL: "BAY 43-9006 inhibition of oncogenic RET mutants.", JOURNAL OF THE NATIONAL CANCER INSTITUTE 1 MAR 2006, vol. 98, no. 5, 1 March 2006 (2006-03-01), pages 326 - 334, XP002448750, ISSN: 1460-2105 *
CHANG YONG S ET AL: "Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models.", CANCER CHEMOTHERAPY AND PHARMACOLOGY APR 2007, vol. 59, no. 5, April 2007 (2007-04-01), pages 561 - 574, XP002464783, ISSN: 0344-5704 *
CLARK JEFFREY W ET AL: "Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH 1 AUG 2005, vol. 11, no. 15, 1 August 2005 (2005-08-01), pages 5472 - 5480, XP002448749, ISSN: 1078-0432 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; 1 October 2004 (2004-10-01), WILHELM SCOTT M ET AL: "BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.", XP002448752, Database accession no. NLM15466206 *
HEIM MARTINA ET AL: "The Raf kinase inhibitor BAY 43-9006 reduces cellular uptake of platinum compounds and cytotoxicity in human colorectal carcinoma cell lines.", ANTI-CANCER DRUGS FEB 2005, vol. 16, no. 2, February 2005 (2005-02-01), pages 129 - 136, XP009088785, ISSN: 0959-4973 *
KUEFER R ET AL: "Translational research in renal cell cancer; Illustrated by the example of the vascular endothelial growth factor pathway", DER UROLOGE, AUSGABE A ; ZEITSCHRIFT FÜR KLINISCHE UND PRAKTISCHE UROLOGIE ORGAN DER DEUTSCHEN GESELLSCHAFT FÜR UROLOGIE, SPRINGER-VERLAG, BE, vol. 45, no. 3, 1 March 2006 (2006-03-01), pages 328 - 335, XP019321736, ISSN: 1433-0563 *
LUO ET AL: "Enhancement of radiation effects by pXLG-mEndo in a lung carcinoma model", INTERNATIONAL JOURNAL OF RADIATION: ONCOLOGY BIOLOGY PHYSICS, PERGAMON PRESS, US, vol. 63, no. 2, 1 October 2005 (2005-10-01), pages 553 - 564, XP005077610, ISSN: 0360-3016 *
SHI Q ET AL: "Constitutive and inducible interleukin 8 expression by hypoxia and acidosis renders human pancreatic cancer cells more tumorigenic and metastatic.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH NOV 1999, vol. 5, no. 11, November 1999 (1999-11-01), pages 3711 - 3721, XP002464785, ISSN: 1078-0432 *
TAMM M ET AL: "Hypoxia-induced interleukin-6 and interleukin-8 production is mediated by platelet-activating factor and platelet-derived growth factor in primary human lung cells.", AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY OCT 1998, vol. 19, no. 4, October 1998 (1998-10-01), pages 653 - 661, XP002464787, ISSN: 1044-1549 *
WOUTERS BRADLY G ET AL: "Targeting hypoxia tolerance in cancer.", DRUG RESISTANCE UPDATES : REVIEWS AND COMMENTARIES IN ANTIMICROBIAL AND ANTICANCER CHEMOTHERAPY FEB 2004, vol. 7, no. 1, February 2004 (2004-02-01), pages 25 - 40, XP002464784, ISSN: 1368-7646 *
XU L ET AL: "Hypoxia-induced elevation in interleukin-8 expression by human ovarian carcinoma cells.", CANCER RESEARCH 15 NOV 1999, vol. 59, no. 22, 15 November 1999 (1999-11-15), pages 5822 - 5829, XP002464786, ISSN: 0008-5472 *

Also Published As

Publication number Publication date
CA2648106A1 (en) 2007-11-01
EP2002264A2 (en) 2008-12-17
WO2007123722A2 (en) 2007-11-01
JP2009532029A (en) 2009-09-10

Similar Documents

Publication Publication Date Title
WO2007123722A3 (en) Methods for prediction and prognosis of cancer, and monitoring cancer therapy
WO2007047955A3 (en) Methods for prediction and prognosis of cancer, and monitoring cancer therapy
WO2007056012A3 (en) Methods for prediction and prognosis of cancer, and monitoring cancer therapy
WO2007059094A3 (en) Methods for prediction and prognosis of cancer, and monitoring cancer therapy
WO2007056011A3 (en) Methods for prediction and prognosis of cancer, and monitoring cancer therapy
WO2010017515A3 (en) Breast cancer specific markers and methods of use
WO2009108860A3 (en) Microrna-based methods and compositions for the diagnosis, pronosis and treatment of prostate related disorders
EP2179037A4 (en) Methods for diagnosis, prognosis and methods of treatment
WO2008153705A3 (en) Methods of treating, diagnosing and detecting fgf21-associated disorders
WO2011037643A3 (en) Compositions and methods for detecting and treating prostate carcinoma
WO2010102195A3 (en) Annexin a11 and associated genes as biomarkers for cancer
WO2007141280A3 (en) Proteins
ZA200808669B (en) Methods of treating, diagnosing or detecting cancer
EP2073843A4 (en) Methods of diagnosing, treating, or preventing plasma cell disorders
MY155340A (en) Use of cathepsin c
WO2008115710A3 (en) Biomarkers for cancer
WO2010037042A3 (en) Methods for detecting and treating cancer
WO2008026008A8 (en) Protein
WO2008069976A3 (en) Compounds and methods for enzyme-mediated tumor imaging and therapy
WO2009098451A3 (en) Biomarkers of aminopeptidase inhibition
WO2006032009A3 (en) Methods for prediction and prognosis of cancer, and monitoring cancer therapy
IL226362A0 (en) Compounds, and methods for the treatment of cancer
WO2012078648A3 (en) Novel method of cancer diagnosis and prognosis and prediction of response to therapy
WO2004028352A3 (en) Methods for prediction and prognosis of cancer, and monitoring cancer therapy
WO2012024302A3 (en) Biomarkers of cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07754481

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2009503038

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2648106

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007754481

Country of ref document: EP